Alnylam Assist: Patient Support Program

Alnylam Assist will provide support for your patients as they begin treatment with AMVUTTRA

Our Case Managers are here to help your patients.

Call Us:


Monday - Friday, 8am - 6pm

Enroll Your Patients

How Alnylam Assist Can Help

Alnylam Assist is committed to providing your patient support throughout treatment with AMVUTTRA. Alnylam Assist offers support services to your patient in 4 key areas

Alnylam Assist® - Understanding Your Benefits

Benefit Verification

Help determining
patient-specific coverage

Alnylam Assist® - Financial Assistance Options

Financial Assistance

Information about patients'
eligibility for financial assistance

Alnylam Assist® - Disease and Treatment Education

Patient Education

Disease and product education
for patients and families

Alnylam Assist® Reimbursement Support Icon

Treatment Access

Education about the prior authorization,
claims, and appeals processes

Forms and Documents

Download the materials below for more information about Alnylam Assist™

See All Forms and Documents ›

Alnylam Assist® - Downloadable PDF

Healthcare Professionals

Alnylam Assist™ Support Services
Overview Brochure


Alnylam Assist® - Downloadable PDF

Patients + Caregivers

Alnylam Assist™ Brochure


Alnylam Assist® Case Managers

Enroll Your Patients

After deciding to prescribe your patient AMVUTTRA, consider enrolling your patient in Alnylam Assist™.

Alnylam Assist® Case Managers


Monday - Friday, 8am - 6pm

Enroll Your Patients

Enrolling Your Patients

Together with your patient
(in office)

Alnylam Assist® electronic Start Form icon

Electronic Start Form

Begin Here ›


Alnylam Assist® Start Form - To Print And Fax

& Fax

Download Form ›

Initiate then send to patient
(via email)

Alnylam Assist® Start Form - To Email To Patient

DocuSign eSignature

Begin Here ›

HCP triangle


Reduced Serum Vitamin A Levels and Recommended Supplementation
AMVUTTRA® (vutrisiran) treatment leads to a decrease in serum vitamin A levels.

Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions
The most common adverse reactions that occurred in patients treated with AMVUTTRA were pain in extremity (15%), arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).


AMVUTTRA® (vutrisiran) is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

For additional information about AMVUTTRA, please see the full Prescribing Information.